In hormone receptor-positive (HR+) breast cancer, the tumor immune microenvironment (TIM) is uniquely shaped by estrogen signaling, which not only suppresses immune activity but also fosters a microenvironment conducive to late recurrence. This makes late recurrence a critical issue that must not be underestimated in these patients.
Estrogen promotes immunosuppressive mechanisms, such as polarizing macrophages toward the M2 subtype and enhancing Tregs and myeloid-derived suppressor cells (MDSCs). Conversely, CDK4/6 inhibitors and endocrine therapies offer a dual benefit: they block estrogen signaling while also reshaping the TIM. CDK4/6 inhibitors, in particular, have shown promise in triggering anti-tumor immunity and reducing recurrence risk. Excitingly, ongoing research is exploring how different CDK4/6 inhibitors uniquely modulate the TIM, potentially paving the way for more precise and effective treatment strategies in HR+ breast cancer.
台灣諾華股份有限公司
台灣諾華承續全球的目標和願景，以研發創新藥品來治療疾病、減輕疾病帶來的痛苦，並提昇病患的生活品質。期望符合甚且超越外界期許，致力創造永續成長，保持業界前茅，維持長期經營成效。希望贏得優異工作環境的美譽、營造鼓勵創新與效率的環境，並能適時回饋社會。